Explanation of
Responses: |
(1) |
Transaction effected
pursuant to a plan established pursuant to Rule 10b5-1. |
(2) |
The shares were sold as
follows: 3,899 by MPM BioVentures 2014, L.P. ("BV 2014"), 134 by
MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 2,463 by
MPM BioVentures 2018, L.P. ("BV 2018"), 49 by MPM Asset Management
Investors BV2018 LLC ("AM BV2018") and 4,407 by UBS Oncology Impact
Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM
BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect
general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the
manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM
BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect
general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the
manager of AM BV2018. Ansbert Gadicke is a managing director of BV
2014 LLC and BV 2018 LLC. |
(3) |
BioImpact Capital LLC
("BioImpact") is the General Partner of Oncology Impact Fund
(Cayman) Management L.P., the General Partner of UBS Oncology
Impact Fund, L.P. Ansbert Gadicke is a managing partner of
BioImpact. Each of the Reporting Persons disclaims beneficial
ownership of the securities herein except to the extent of his or
its respective pecuniary interest therein, if any. |
(4) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $34.915 to $35.91 inclusive.
The Reporting Person undertakes to provide to the Issuer, any
security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the
number of shares sold at each separate price within the range set
forth in this footnote. |
(5) |
The shares are held as
follows: 1,721,258 by BV 2014, 97,289 by MPM BioVentures 2014(B),
L.P. ("BV 2014(B)"), 59,245 by AM BV2014, 1,087,109 by BV 2018,
48,966 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 21,453 by
AM BV2018 and 1,945,654 by UBS Oncology. Each of the Reporting
Persons disclaims beneficial ownership of the securities herein
except to the extent of his or its respective pecuniary interest
therein, if any. |
(6) |
The shares were sold as
follows: 3,652 by BV 2014, 126 by AM BV2014, 2,306 by BV 2018, 45
by AM BV2018 and 4,129 by UBS Oncology. |
(7) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $35.92 to $36.39 inclusive. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
(8) |
The shares are held as
follows: 1,717,606 by BV 2014, 97,289 by BV 2014(B), 59,119 by AM
BV2014, 1,084,803 by BV 2018, 48,966 by BV 2018(B), 21,408 by AM
BV2018 and 1,941,525 by UBS Oncology. Each of the Reporting Persons
disclaims beneficial ownership of the securities herein except to
the extent of his or its respective pecuniary interest therein, if
any. |
(9) |
The shares were sold as
follows: 6,001 by BV 2014, 207 by AM BV2014, 3,790 by BV 2018, 75
by AM BV2018 and 6,783 by UBS Oncology. |
(10) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $34.06 to $34.86 inclusive. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
(11) |
The shares are held as
follows: 1,711,605 by BV 2014, 97,289 by BV 2014(B), 58,912 by AM
BV2014, 1,081,013 by BV 2018, 48,966 by BV 2018(B), 21,333 by AM
BV2018 and 1,934,742 by UBS Oncology. Each of the Reporting Persons
disclaims beneficial ownership of the securities herein except to
the extent of his or its respective pecuniary interest therein, if
any. |
(12) |
The shares were sold as
follows: 178 by BV 2014, 6 by AM BV2014, 112 by BV 2018, 2 by AM
BV2018 and 202 by UBS Oncology. |
(13) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $35.125 to $35.67 inclusive.
The Reporting Person undertakes to provide to the Issuer, any
security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the
number of shares sold at each separate price within the range set
forth in this footnote. |
(14) |
The shares are held as
follows: 1,711,427 by BV 2014, 97,289 by BV 2014(B), 58,906 by AM
BV2014, 1,080,901 by BV 2018, 48,966 by BV 2018(B), 21,331 by AM
BV2018 and 1,934,540 by UBS Oncology. Each of the Reporting Persons
disclaims beneficial ownership of the securities herein except to
the extent of his or its respective pecuniary interest therein, if
any. |